Virpax Pharmaceuticals Announces Leadership Transition
Retrieved on:
Friday, November 17, 2023
Biotechnology, Health, Finance, Other Health, Pharmaceutical, Surgery, Professional Services, Other Science, Practice Management, Medical Devices, Infectious Diseases, Hospitals, Science, Veterinary, CNS, Neurogenic inflammation, Silence Therapeutics, Meharry Medical College, Pharmaceutical marketing, Regulatory affairs, Therapy, Post-traumatic stress disorder, Quality assurance, Lincoln University, Commercial Operating System, Pain management, Patient, INSEAD, Merck, Medication, Clobazam, Nitrome, Sanofi, Trustee, Novartis, University, Harvard Medical School, Axovant Sciences, Tennessee State University, Champaign–Urbana metropolitan area, Central nervous system, Business, DSM-IV codes, International business, Pharmaceutical industry, Management, Analgesic, Schizophrenia, Biology, Neurophysiology, Lundbeck, Neuroscience, Droxidopa
Prior to Virpax, Mr. Bruce served as Vice President of sales for Danone Specialized Nutrition North America, Danone’s medical nutrition division.
Key Points:
- Prior to Virpax, Mr. Bruce served as Vice President of sales for Danone Specialized Nutrition North America, Danone’s medical nutrition division.
- He has a BA from Lincoln University and a Master’s degree in Leadership from Georgetown University’s McDonough School of Business.
- Aside from Virpax Pharmaceuticals, he also serves on the board of Advent Therapeutics Inc. and is a member of the Board of Trustees of Meharry Medical College.
- I am proud of what we have accomplished together and confident that Virpax under Gerald and Eric’s leadership will remain on track to begin first-in-human trials in the coming year,” commented Mr. Mack.